Studying Tumor Initiating Cell (TIC) Heterogeneity and Treatment Resistance by Single-Cell Microfluidics Technology

Lidong Qin

DOI: https://doi.org/10.4172/2168-9431.1000e112

2012-01-01

Abstract:Copyright: © 2012 Qin L. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. In 2003, Clarke and colleagues used limiting dilution transplantation of CD44+/CD24cells into the mammary fat pad of immunecompromised nonobese diabetic/severe-combined immunodeficiency (NOD-SCID) mice and provided the first evidence of a Tumor Initiating Cell (TIC) subpopulation from breast cancer pleural effusions [1]. Recent investigations from both animal models and clinical samples have continuously supported that TIC does exist and plays an important role in tumor metastasis and recurrence [1,2]. However, TICs have a few intrinsic properties leading to their complexity in molecular targeting and inhibition. TICs are 1) heterogeneous [3-7], 2) dynamically changing states [8,9], 3) often rare [1,10] and 4) lack robust biomarker combinations [4], thereby challenging conventional bulk in vitro experimental tools and complicating the prediction and explanation of animal study results. High throughput, in situ, and cellby-cell measurement on TICs is a way to fully decipher TIC’s molecular signature and signaling pathways. We believe such measurement can lead to 1) revolutionary implementation of TIC models; 2) identification of new therapeutic targets; and 3) reduction of breast cancer recurrence and metastasis. Microfluidics technology is a candidate to serve as such type of high throughput single-cell characterization.